Condition: Breast Neoplasm Malignant Female · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after vacuum assisted breast biopsy (VABB) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for highly selected patients, in whom systemic treatments have provided the maximum response.
This description comes directly from the study's public registry record.
Massimiliano Gennaro, MD · +390223903246 · massimiliano.gennaro@istitutotumori.mi.it
Kiara Muca · +390223903908 · kiara.muca@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Nazionale Tumori Milano | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06938724